Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment

Divine C. Nwafor  
*West Virginia University*

Allison L. Brichacek  
*West Virginia University*

Afroz S. Mohammad  
*West Virginia University*

Jessica Griffith  
*West Virginia University*

Brandon P. Lucke-Wold  
*West Virginia University*

See next page for additional authors

Follow this and additional works at: [https://researchrepository.wvu.edu/faculty_publications](https://researchrepository.wvu.edu/faculty_publications)

Part of the [Neurosciences Commons](https://researchrepository.wvu.edu/faculty_publications)

**Digital Commons Citation**  
Nwafor, Divine C.; Brichacek, Allison L.; Mohammad, Afroz S.; Griffith, Jessica; Lucke-Wold, Brandon P.; Benkovic, Stanley A.; Geldenhuys, Werner J.; Lockman, Paul R.; and Brown, Candice M., "Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment" (2019). *Faculty Scholarship*. 1312.  
[https://researchrepository.wvu.edu/faculty_publications/1312](https://researchrepository.wvu.edu/faculty_publications/1312)

This Article is brought to you for free and open access by The Research Repository @ WVU. It has been accepted for inclusion in Faculty Scholarship by an authorized administrator of The Research Repository @ WVU. For more information, please contact [ian.harmon@mail.wvu.edu](mailto:ian.harmon@mail.wvu.edu).
Authors
Divine C. Nwafor, Allison L. Brichacek, Afroz S. Mohammad, Jessica Griffith, Brandon P. Lucke-Wold, Stanley A. Benkovic, Werner J. Geldenhuys, Paul R. Lockman, and Candice M. Brown

This article is available at The Research Repository @ WVU: https://researchrepository.wvu.edu/faculty_publications/
Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment

Divine C Nwafor1,2, Allison L Brichacek3,4, Afroz S Mohammad5*, Jessica Griffith5*, Brandon P Lucke-Wold7†, Stanley A Benkovic2, Werner J Geldenhuys1,5, Paul R Lockman1,5 and Candice M Brown1,2,3,4,6.

1Graduate Programs in Neuroscience, Department of Neuroscience, School of Medicine, Health Sciences Center, West Virginia University, Morgantown, WV, USA. 2Department of Neuroscience, School of Medicine, Health Sciences Center, West Virginia University, Morgantown, WV, USA. 3Immunology and Microbial Pathogenesis, School of Medicine, Health Sciences Center, West Virginia University, Morgantown, WV, USA. 4Department of Microbiology, Immunology, and Cell Biology, School of Medicine, Health Sciences Center, West Virginia University, Morgantown, WV, USA. 5Department of Pharmaceutical Sciences, School of Pharmacy, Health Sciences Center, West Virginia University, Morgantown, WV, USA. 6Center for Basic and Translational Stroke Research, Rockefeller Neuroscience Institute, Health Sciences Center, West Virginia University, Morgantown, WV, USA.

ABSTRACT: Sepsis is a systemic inflammatory disease resulting from an infection. This disorder affects 750,000 people annually in the United States and has a 62% rehospitalization rate. Septic symptoms range from typical flu-like symptoms (eg, headache, fever) to a multifactorial syndrome known as sepsis-associated encephalopathy (SAE). Patients with SAE exhibit an acute altered mental status and often have higher mortality and morbidity. In addition, many sepsis survivors are also burdened with long-term cognitive impairment. The mechanisms through which sepsis initiates SAE and promotes long-term cognitive impairment in septic survivors are poorly understood. Due to its unique role as an interface between the brain and the periphery, numerous studies support a regulatory role for the blood-brain barrier (BBB) in the progression of acute and chronic brain dysfunction. In this review, we discuss the current body of literature which supports the BBB as a nexus which integrates signals from the brain and the periphery in sepsis. We highlight key insights on the mechanisms that contribute to the BBB’s role in sepsis which include neuroinflammation, increased barrier permeability, immune cell infiltration, mitochondrial dysfunction, and a potential barrier role for tissue non-specific alkaline phosphatase (TNAP). Finally, we address current drug treatments (eg, antimicrobials and intravenous immunoglobulins) for sepsis and their potential outcomes on brain function. A comprehensive understanding of these mechanisms may enable clinicians to target specific aspects of BBB function as a therapeutic tool to limit long-term cognitive impairment in sepsis survivors.

KEYWORDS: Sepsis, sepsis-associated encephalopathy, blood-brain barrier, neuroinflammation, drug delivery, tissue non-specific alkaline phosphatase

Introduction

Sepsis is a debilitating systemic inflammatory process involving multiple organ systems that is preceded by an infection. It is the 10th leading cause of death in the United States with an annual financial burden for patients and survivors that exceeds $20 billion. Through mechanisms that remain largely poorly understood, sepsis can induce acute and chronic changes in the central nervous system (CNS), particularly at the blood-brain barrier (BBB). A compromised CNS can lead to sepsis-associated encephalopathy (SAE), a well-characterized state of cognitive impairment and neurological dysfunction often seen in the acute phase of sepsis. Multiple pathways have been investigated for their contribution to the sepsis-associated compromise of the BBB. This review integrates current clinical knowledge of sepsis with mechanistic insights from both clinical studies and preclinical animal models of sepsis. The overall goal of this review is to understand how sepsis pathophysiology perturbs the integral functions of the cells and proteins that comprise the BBB. Thus, we provide insights to uncover how a compromised BBB may lead to SAE or permanent brain dysfunction in sepsis survivors.

Sepsis Pathophysiology

Clinical sepsis presentation

The current definition from the Sepsis-3 consortium describes sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to an infection. The most common precipitating sites for sepsis are the respiratory system,
Sepsis may present as a combination of various non-descript signs and symptoms making early diagnosis difficult. For example, patients may present with fever, cold, pain, delirium, increased heart rate, shortness of breath, diarrhea, and/or low blood pressure. The diagnosis and management of sepsis has changed dramatically over 30 years. The historical definition of sepsis was focused primarily on inflammation and incorrectly portrayed sepsis as a sequential process that eventually ends in septic shock (Figure 1A). In 2016, Sepsis-2 criteria were revised to current Sepsis-3 criteria to improve consistency in classification in epidemiological and clinical trials. The revised Sepsis-3 classification shown in Figure 1B focuses on accelerated recognition and management of sepsis.

In recent years, the focus in clinical treatment has shifted to severe sepsis and septic shock, which has increased survival in hospitalized patients diagnosed with severe sepsis and critically ill patients with septic shock who have a higher risk of multi-organ failure complications and death. This heterogeneous presentation of clinical sepsis makes disease management and appropriate therapeutic interventions difficult. Some challenges associated with the management of sepsis include late diagnoses, poor prognoses, inadequate therapeutics, and post-sepsis complications. These challenges stem from late recognition and difficulties associated with differentiation of sepsis from other illnesses in its early stage. In the later stages of sepsis, recognition becomes easier, yet sepsis is more difficult to treat and often coincides with multi-organ failure.

Most sepsis cases are hospital acquired and are often comorbid with prior injury, such as stroke, trauma, or postsurgery. Most cases of hospital-acquired sepsis are treated in the intensive care unit (ICU). However, ICU heterogeneity can make sepsis more common in one ICU versus another. For example, there is a higher incidence of sepsis in a trauma ICU as opposed to a surgical ICU. Alternatively, a significant number of sepsis patients are admitted to the hospital or directly to the ICU via the Emergency Department (ED); most of these patients present with community-acquired sepsis from pneumonia or complications from other comorbid conditions such as diabetes. In addition to the patient setting, the development of sepsis often depends on several risk factors, such as age, where a proportionate relationship exists between increasing age and sepsis acquisition. Male sex, non-white ethnicity, and preexisting conditions such as Alzheimer disease (AD), HIV, or cancer are also risk factors for acquisition.
Current experimental animal models of sepsis

Understanding the mechanisms involved in the pathophysiology of sepsis requires the use of animal models that adequately reproduce several features of the human disorder including both inflammation and infection. The most common animal models are cecal ligation and puncture (CLP), the colon ascendens stent peritonitis (CASP) model, endotoxin injection, and bacterial infusion. The CLP model is regarded as the gold standard for human-like sepsis progression in animal models. Execution of this model necessitates leakage of polymicrobial feces into the peritoneum after the cecum is punctured with a needle. Disease severity is modeled by controlling needle size and number of punctures; however, a major limitation of this model is the failure to maintain continuous fecal leakage due to abscess formation and necrosis of the punctured bowel. Some investigators also administer antibiotics either at the time of injury or at intervals post injury. Although antibiotic administration is an additional feature which mimics the treatment regimen in human patients, the use of different antibiotic classes and dosing paradigms across laboratories may confound the interpretation of findings when results are compared between laboratories. The CASP model is a newer model recently introduced to counter the flaws of the CLP model. The model involves the insertion of a stent at the ascending portion of the colon, allowing continual leakage of feces into the peritoneum. Despite resemblance to human-like sepsis progression, the drawbacks to this model include animal variation in colon size, fecal content, and the volume of feces that leaks into the peritoneum. Although these two models have provided remarkable insights to understand the pathophysiology of sepsis in humans, they fail to fully recapitulate the comprehensive clinical progression of sepsis in humans.

Two alternative sepsis models involve injection or infusion of endotoxin or bacteria. The endotoxin model typically involves injection of lipopolysaccharide (LPS) endotoxin, a component of Gram-negative bacterial cell walls which signals most commonly through toll-like receptor-4 (TLR4). Administration of LPS via different routes (ie, intraperitoneal, intravenous, or intracerebroventricular) initiates a cytokine storm that results in the release of tumor necrosis factor alpha (TNF-α) and numerous interleukins (ILs; IL-1, IL-6, and IL-10). Injection of LPS mimics many classical signs and symptoms of sepsis-induced inflammation, thereby providing a basic understanding of how inflammation activates the immune response in sepsis. One major limitation of the LPS model is the lack of integration of the infection component. A second limitation is that very large endotoxin doses are required in many rodent models to mimic the pathological profile of the clinical sepsis picture observed in humans. Bacterial injection is a less widely used model involving infusion of a bacterium, usually *Escherichia coli* or *Staphylococcus aureus*, to initiate both inflammation and infection. Different bacterial strains used for infection present a challenge in this model, as they will produce different patterns of sepsis progression. Thus, the characteristics of the sepsis model must be considered when interpreting the effects of sepsis on the CNS and other organ systems.

The CNS in sepsis: sickness behavior and SAE

A critical role for the CNS in the pathophysiology of sepsis has emerged over the past 2 decades. Several recent reviews address this topic in excellent detail. One important contribution of the CNS is “sickness behavior.” Sickness behavior is a response seen in sepsis characterized by fever, adaptive behavioral changes, and neuroimmune changes. The response is governed primarily by systemic interactions with the vagus nerve (VN) and circumventricular organs (CVOs). The VN is an important mediator of inflammation. Septic mice that underwent a vagotomy (VGX) surgery exhibited an increase in the synthesis of inflammatory cytokines compared with sepsis-only mice. In contrast, stimulation of the VN in septic animals resulted in an overall reduction in the synthesis of inflammatory cytokines, leukocyte recruitment, and endothelial activation. The VN also relays peripheral information to the medullary autonomic nuclei, whereas the CVOs may serve as sensors for inflammatory mediators, primarily cytokines, and serve as the foci for neuroimmune communication between the peripheral circulation into the brain parenchyma. Many of these neuroimmune communication circuits are well described, but the underlying mechanisms that regulate these pathways remain poorly understood. For example, activation of the nucleus tractus solitarii and locus coeruleus by inflammatory mediators subsequently activates autonomic nuclei, behavioral, and neuroendocrine centers. The summative effect can be observed as depression, social withdrawal, increased heart rate, poor blood pressure control, or altered vigilance. In addition to sickness behavior, patients with acute sepsis may have changes in brain function that present as delirium, seizures, psychological disorders, abnormal motor movements, and increased mortality. Changes in brain function are most commonly manifested as delirium. Whereas sepsis-associated delirium usually presents as decreased activity, a hyperactive form associated with agitation may be seen in some patients. Tools that can be used to confirm sepsis-associated delirium include medical history, blood chemistry, electrolyte balance, the ICU screening checklist, Confusion Assessment Method, and Glasgow Coma Scale. Sickness behavior and/or delirium may progress to a more severe phenotype, SAE, which is regarded as a diagnosis of exclusion. It is characterized by impaired consciousness, seizures, delirium, coma, focal cognitive deficits, and alterations in electroencephalogram (EEG) patterns. Patients with SAE have increased mortality, long-term neurological decline, memory lapse, inattentiveness, disorientation, and verbal difficulties.
Alterations in EEG wave patterns often predict SAE outcome, and EEG reactivity is associated with mortality even at 1 year post severe sepsis. For example, a recent study showed resting-state EEG changes in sepsis survivors at 6 to 24 months after hospital discharge, including increased delta and sigma activity compared with control patients. Changes in EEG frequencies can be associated with changes in brain function. For example, slowing alpha activity with increased theta activity reflects cortical dysfunction and can occur in patients with mild to moderate encephalopathy. Slowing of delta activity is often associated with more severe neurocognitive decline and indicates impaired function in deeper brain structures, such as the basal ganglia. Whereas the evaluation of EEG can be sensitive to SAE diagnosis in the absence of neurological examination abnormalities, it has poor specificity and can be hampered by sedation and analgesia.

Ischemia is another common complication of early sepsis due to drastic changes in systemic blood pressure. A number of human clinical studies support the premise of decreased cerebral blood flow (CBF) in acute sepsis. The abrupt change in blood pressure with added sepsis-associated coagulopathy causes reduced blood flow to neurons. The hippocampal region and watershed areas are affected more often than other brain regions when this occurs. Autopsies in patients who died from septic shock revealed consistent ischemic and hypoxic insults in regions when this occurs. Autopsies in patients who died from septic shock revealed consistent ischemic and hypoxic insults in areas particularly susceptible to low blood flow (eg, amygdala, frontal junctional cortex, etc) and in autonomic centers. The presence of ischemia in post-mortem studies strongly suggest that vascular irregularities and alterations of CBF occur during sepsis. Importantly, multiple clinical observations support the concept that, in the absence of cerebrovascular occlusion (ie, stroke), impaired cerebral autoregulation and hypotension may be the primary drivers of tissue hypoxia and cerebral ischemia observed in sepsis patients.

A recent study in rats conducted by Towner et al showed that CBF in the thalamus and cortex is significantly increased 24 hours post LPS injection but significantly reduced 6 weeks post LPS injection when compared with saline controls. Preceding human clinical studies also support the decrease in CBF at 24 hours observed by Towner and colleagues, yet there remains a paucity of literature on how sepsis may affect long-term CBF in human patients. Overall, coincident alterations in cerebral blood and cardiovascular collapse in sepsis emphasize the importance of fluid resuscitation as a crucial component of sepsis management. The ideal type of fluid (colloid vs crystalloids) and ideal composition used to treat septic patients remains controversial. A total of 3 clinical trials demonstrated that colloid use in sepsis treatment failed to show a clear benefit. In addition to the findings from this study, the restricted accessibility, safety issues, and the expensive value of colloids shifted the debate toward identifying the ideal crystalloid composition (eg, Ringer lactate, Ringer acetate, etc). We refer the reader to excellent reviews regarding optimal fluid therapeutic strategies in sepsis.

The utilization of magnetic resonance imaging (MRI) in the diagnosis of SAE offers a unique opportunity in capturing some of the morphologic, ischemic, and metabolic alterations associated with sepsis. A summary of MRI findings in acute sepsis is shown in Table 1. In particular, diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) are 2 MRI modalities currently used in assessing BBB breakdown caused by vasogenic (extracellular) or cytotoxic (intracellular) edema. Cytotoxic edema typically caused by ischemia, hypoxia, or vasogenic edema is the most consistently reported MRI change associated with SAE. Early detection of BBB breakdown by gadolinium (Gd) could establish an adequate therapeutic window for current and future septic treatments, but human studies are limited. A recent study in rats revealed a significant increase in the infiltration of Gd in the cortex, hippocampus, and thalamus 24 hours and 1 week post LPS injection. Gd use may also cause a substantial risk of nephrogenic systemic fibrosis, a risk factor which suggests that Gd-based imaging in the CNS should be evaluated on a case-by-case basis.

Sedatives are often administered in the ICU when treating sepsis. A study conducted by Qiao et al in rats showed that the application of dexmedetomidine and midazolam improved survival and reduced cytokine levels and splenic apoptosis in septic mice. Another systematic review by Zamani et al emphasized the importance of the kind of sedative used in treating sepsis; the findings from this study revealed that dexmedetomidine improved short-term mortality when compared with other sedatives. It is widely thought that the neuroprotective effects of dexmedetomidine result from neuronal death prevention, suppression of inflammatory cytokines, and modulation of neurotransmitters released in the sympathetic nervous system. However, a limitation noted by Zamani et al was the small sample size included in the clinical studies. It is important to note that the tools used in the confirmation of sepsis-associated delirium are not helpful in ICU-sedated patients who may otherwise exhibit signs of delirium.

Sepsis also affects long-term neurological outcomes. The greatest risk factor for long-term impairment is the duration of delirium in the acute phase of sepsis and the increased ventricle-to-brain ratio as calculated by MRI. A seminal study published by Iwashyna et al suggested that up to 70% of sepsis survivors may exhibit lasting neurological impairment, including alterations in mood, cognition, and motor function. Cognitive, motor, and mood impairments are three of the most common long-term neurological outcomes in septic patients. Current evidence also suggests an increased susceptibility to other neurodegenerative disorders such as stroke or AD post sepsis insult. Thus, patient populations that are the most

The utilization of magnetic resonance imaging (MRI) in the diagnosis of SAE offers a unique opportunity in capturing some of the morphologic, ischemic, and metabolic alterations associated with sepsis. A summary of MRI findings in acute sepsis is shown in Table 1. In particular, diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) are 2 MRI modalities currently used in assessing BBB breakdown caused by vasogenic (extracellular) or cytotoxic (intracellular) edema. Cytotoxic edema typically caused by ischemia, hypoxia, or vasogenic edema is the most consistently reported MRI change associated with SAE. Early detection of BBB breakdown by gadolinium (Gd) could establish an adequate therapeutic window for current and future septic treatments, but human studies are limited. A recent study in rats revealed a significant increase in the infiltration of Gd in the cortex, hippocampus, and thalamus 24 hours and 1 week post LPS injection. Gd use may also cause a substantial risk of nephrogenic systemic fibrosis, a risk factor which suggests that Gd-based imaging in the CNS should be evaluated on a case-by-case basis.

Sedatives are often administered in the ICU when treating sepsis. A study conducted by Qiao et al in rats showed that the application of dexmedetomidine and midazolam improved survival and reduced cytokine levels and splenic apoptosis in septic mice. Another systematic review by Zamani et al emphasized the importance of the kind of sedative used in treating sepsis; the findings from this study revealed that dexmedetomidine improved short-term mortality when compared with other sedatives. It is widely thought that the neuroprotective effects of dexmedetomidine result from neuronal death prevention, suppression of inflammatory cytokines, and modulation of neurotransmitters released in the sympathetic nervous system. However, a limitation noted by Zamani et al was the small sample size included in the clinical studies. It is important to note that the tools used in the confirmation of sepsis-associated delirium are not helpful in ICU-sedated patients who may otherwise exhibit signs of delirium.

Sepsis also affects long-term neurological outcomes. The greatest risk factor for long-term impairment is the duration of delirium in the acute phase of sepsis and the increased ventricle-to-brain ratio as calculated by MRI. A seminal study published by Iwashyna et al suggested that up to 70% of sepsis survivors may exhibit lasting neurological impairment, including alterations in mood, cognition, and motor function. Cognitive, motor, and mood impairments are three of the most common long-term neurological outcomes in septic patients. Current evidence also suggests an increased susceptibility to other neurodegenerative disorders such as stroke or AD post sepsis insult. Thus, patient populations that are the most

The utilization of magnetic resonance imaging (MRI) in the diagnosis of SAE offers a unique opportunity in capturing some of the morphologic, ischemic, and metabolic alterations associated with sepsis. A summary of MRI findings in acute sepsis is shown in Table 1. In particular, diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) are 2 MRI modalities currently used in assessing BBB breakdown caused by vasogenic (extracellular) or cytotoxic (intracellular) edema. Cytotoxic edema typically caused by ischemia, hypoxia, or vasogenic edema is the most consistently reported MRI change associated with SAE. Early detection of BBB breakdown by gadolinium (Gd) could establish an adequate therapeutic window for current and future septic treatments, but human studies are limited. A recent study in rats revealed a significant increase in the infiltration of Gd in the cortex, hippocampus, and thalamus 24 hours and 1 week post LPS injection. Gd use may also cause a substantial risk of nephrogenic systemic fibrosis, a risk factor which suggests that Gd-based imaging in the CNS should be evaluated on a case-by-case basis.

Sedatives are often administered in the ICU when treating sepsis. A study conducted by Qiao et al in rats showed that the application of dexmedetomidine and midazolam improved survival and reduced cytokine levels and splenic apoptosis in septic mice. Another systematic review by Zamani et al emphasized the importance of the kind of sedative used in treating sepsis; the findings from this study revealed that dexmedetomidine improved short-term mortality when compared with other sedatives. It is widely thought that the neuroprotective effects of dexmedetomidine result from neuronal death prevention, suppression of inflammatory cytokines, and modulation of neurotransmitters released in the sympathetic nervous system. However, a limitation noted by Zamani et al was the small sample size included in the clinical studies. It is important to note that the tools used in the confirmation of sepsis-associated delirium are not helpful in ICU-sedated patients who may otherwise exhibit signs of delirium.

Sepsis also affects long-term neurological outcomes. The greatest risk factor for long-term impairment is the duration of delirium in the acute phase of sepsis and the increased ventricle-to-brain ratio as calculated by MRI. A seminal study published by Iwashyna et al suggested that up to 70% of sepsis survivors may exhibit lasting neurological impairment, including alterations in mood, cognition, and motor function. Cognitive, motor, and mood impairments are three of the most common long-term neurological outcomes in septic patients. Current evidence also suggests an increased susceptibility to other neurodegenerative disorders such as stroke or AD post sepsis insult. Thus, patient populations that are the most
vulnerable to long-term neurologic decline post sepsis are the elderly and patients with preexisting neurodegenerative diseases. The consequences of sepsis on both acute and chronic neurological outcomes demonstrate a critical need to understand the mechanisms involved in SAE development. Harnessing this knowledge will provide essential therapeutic avenues to limit SAE progression and protect against long-term neurological impairment or dysfunction. The remainder of this review will focus on the role of the BBB in sepsis-associated cognitive dysfunction, as preclinical and clinical investigations have uncovered 3 primary BBB-linked mechanisms that contribute to the cause of SAE and the associated short-term and long-term cognitive dysfunction: (1) activation of neuroinflammation, (2) microcirculatory dysfunction, and (3) increased neuronal excitotoxicity.

### Mechanisms of BBB Dysfunction in Sepsis

**BBB overview**

This section will provide a brief overview of the cell biology and physiology of the BBB, as the focus of this review is the BBB in sepsis. BBB and other associated cell types within the neurovascular unit that are affected by sepsis are shown in Table 2. The BBB is a highly selective, dynamic, and semi-permeable biological interface between the brain parenchyma and cerebral circulation. Preservation of BBB integrity protects normal brain function and is dependent on maintaining a precise cerebral homeostasis driven, in large part, by ion and gas concentrations and nutrient availability. The BBB's unique structure is composed of endothelial cells, astrocytes, pericytes, and a basal lamina. The endothelial cells are joined by tight...
Neuroinflammation and BBB permeability

A probable starting point of sepsis-induced acute brain dysfunction is the initiation of neuroinflammation, but the mechanism by which this occurs is not well understood.51 Neuroinflammation is a response to CNS disruption or dysfunction and is typically found in all neurological disorders.114 Current literature suggests that neuroinflammation in sepsis begins when immune cells recognize foreign pathogen-associated molecular patterns (PAMPs) such as LPS, flagellin, fimbriae, peptidoglycan, heat shock proteins, and DNA fragments, which are encoded as "danger signals" to the host. Recognition of PAMPs causes the release of proinflammatory cytokines in the periphery.115 Inflammatory mediators may enter the brain by numerous mechanisms that include transcellular diffusion, solute carrier proteins, receptor-mediated transcytosis, and adsorptive transcytosis.37 Many cytokines enter the brain through receptor-mediated endocytosis on brain endothelial cells. For example, during inflammation, TNF-α is upregulated and its transportation from blood to brain parenchyma is increased, primarily through receptor-mediated endocytosis of its receptors, tumor necrosis factor receptor 1 (TNFR1) and tumor necrosis factor receptor 2 (TNFR2).116,117 Molecules originating in peripheral or CNS tissues may activate vascular endothelium and various leukocytes to produce hormones that facilitate their entry into the brain. For example, Nishijima et al.118 observed that prostaglandin E2 enhanced transport of serum-insulin-like growth factor 1 across the BBB.

Cytokine production contributes to neuronal dysfunction in sepsis in addition to many other neurological disorders. Cytokine infiltration enhances the activation of endothelial cells and microglia, which ultimately leads to loss of neuronal function. Activation of the endothelium leads to enhanced activity of the coagulation cascade, microthrombus formation, and ischemia, which, in turn, promotes increased BBB permeability and leukocyte infiltration. This process triggers neuronal damage, apoptosis, and brain edema.119,120 Cytokine-mediated microglial activation occurs simultaneously with endothelial cell activation. Although the normal microglial response is to phagocytose-injured neuronal cells and clear debris, sustained and dysregulated microglial activation is highly detrimental to specific regions of the CNS. Thus, persistent microglial activation enhances the production of inflammatory cytokines and reactive oxygen species (ROS), which perpetuates a vicious cycle of increased BBB permeability coupled with neuronal damage and apoptosis.116,119 Collectively, neuronal apoptosis and microglial activation are 2 primary mechanisms that increase the activity of inducible nitric oxide synthase (iNOS) activity and generation of nitric oxide (NO). Neuronal apoptosis is further exacerbated due to neuronal sensitivity from increased levels of NO produced by activated microglia.121,122 Intriguingly, iNOS levels are elevated in sepsis and are highest in deceased septic patients.70,100 This increased iNOS activity could also be responsible for the cardiovascular collapse seen in sepsis.53,100,117 It is likely that this cardiovascular collapse also affects the cerebral microcirculation and leads to subsequent sepsis-associated brain dysfunction.

Sepsis, particularly Gram-negative sepsis, has been shown to upregulate caveolin-1 at the endothelial membrane.123 Increased caveolin-1 has recently been shown to increase the amount of peripheral immune infiltration into the brain.124 The mechanisms by which this occurs are not completely understood, but new preclinical studies have shed light on some prevailing theories. Wu et al.125 found that caveolin-1 facilitates T-cell trafficking into the CNS via intercellular adhesion molecule 1 (ICAM-1)–mediated signaling. Caveolin-1 causes acid sphingomyelinase to interact with ICAM-1 increasing the binding affinity for peripheral immune cells.126 Once activated, ICAM-1 facilitates peripheral immune cell diapedesis into the brain. This process occurs via Src phosphorylation within endothelial cells and a subsequent conformational change to ICAM-1, which directly induces the transcellular migration.127 The leaky BBB enhances the entire process during sepsis. After entering the brain, T cells are recruited toward damaged glia via cytokine release. Recent evidence suggests that IL-17A aids this migration process.128 In addition, T cells are helped by astrocytes to re-cross the leaky BBB and carry information about the status of the brain to the rest of the body.129 It is postulated that the peripheral immune cells also release cytokines that maintain the leakiness of the BBB as they exit the brain. When and how long this cross-talk between microglia and peripheral immune cells persists remains to be elucidated. The feedback loop has, however, been implemented in non-autonomous neuronal death.130 The brain regions most susceptible are the nigra–striatal pathway and hippocampus.131 Future studies are warranted to further characterize the brain/immune communication network and, in
particular, where the peripheral immune cells ultimately reside after exiting the brain. Collectively, these mechanisms represent the complicated and multifactorial mechanisms that must be involved in sepsis at the BBB. An integrated overview of the brain and peripheral mechanisms found in acute sepsis is shown in Figure 2.

**Mitochondrial dysfunction**

Mitochondrial dysfunction is a common consequence of sepsis. It has been described in a number of studies with substantial evidence pointing toward oxidative stress as a contributing factor. This literature is summarized in several excellent reviews. The abnormality in the function of the mitochondria plays a role in the development of post-sepsis behavioral, psychological, and cognitive dysfunctions such as SAE. At the cellular level, reactive nitrogen species (RNS), like NO, and ROS, such as peroxynitrite (ONOO\(^-\)), inhibit complexes I and IV of the electron transport chain (ETC). This inhibition produces a subsequent decrease in oxygen consumption and permits the buildup of O\(_2^-\) species and the eventual leakage of this species across the ETC along with other ROS/RNS. The leaked species activate uncoupling proteins that cause an increased H\(^+\) (proton) permeability from the inner mitochondria into the mitochondrial matrix to form oxide ions. Ultimately, these ions are converted to water without any adenosine triphosphate (ATP) generation. Positive feedback of the disrupted BBB on neuroinflammation and potential amplification of this feedback is indicated by the solid bidirectional arrow (direct feedback) and the dotted arrow (indirect feedback).

BBB, blood-brain barrier; CP, choroid plexus; CVOs, circumventricular organs; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; NO, nitric oxide.
The course of infection, type and amount of ROS/RNS, and the brain regions where oxidative stress occurs are important when investigating the timing of oxidative damage leading to mitochondrial dysfunction. Recent studies in rats using thiobarbituric acid and protein carbonyls as markers of lipid and protein oxidation, respectively, have suggested that lipid peroxidation is consistent and widely distributed in the hippocampus, cerebellum, and cortex 6 hours post CLP, whereas oxidative damage due to protein oxidation was largely restricted to the hippocampus. Investigators also identified a concomitant imbalance in the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT). They found that the SOD activity increased in the first 6 hours post sepsis, whereas both SOD and CAT activity levels were decreased compared with sham-injured mice at 12 to 96 hours. Taken together, these findings suggest that oxidative damage in the CNS occurs much earlier than expected in sepsis. Expanding on these findings, Barichello et al used N-acetylcysteine (NAC) and deferroxamine (DFX) antioxidants as a therapeutic intervention in male rats at 6 hours post CLP. They found that the combined administration of NAC and DFX reduced oxidative hippocampal damage, but not when administered separately.

These results further emphasize the importance of all CNS antioxidant systems and signify that multiple targets are required for adequate therapeutic efficacy in sepsis.

Overall, the systemic immune response in sepsis accelerates the increased generation of ROS/RNS, which, in turn, promotes lipid peroxidation in the cerebrovasculature and brain parenchyma. The continued assault from the periphery perpetuates a vicious cycle of ROS/RNS generation between the brain and the periphery. As the overproduction of ROS/RNS overwhelms the capacity of the antioxidant system, the end results manifest as neuroinflammation, ischemia, and increased BBB permeability. Most importantly, the vicious cycle promotes an impaired oxidative metabolism which persists throughout the duration of sepsis and likely continues after recovery. Thus, sustained production of ROS/RNS after recovery is hypothesized to be another mechanism that contributes to long-term neurological impairment post sepsis.

**Putative role of tissue non-specific alkaline phosphatase at the BBB**

The identification of unexplored membrane proteins may be key to better understanding the specific barrier functions of the BBB in disease states such as sepsis. In turn, this knowledge may provide novel therapeutic targets for intervention. One potential therapeutic target localized primarily to the surface of brain endothelial cells is the non-specific isoform of alkaline phosphatase (AP). The enzyme AP has been shown to play an integral role in the regulation of inflammation and can be found either as a soluble form in the peripheral circulation or as a membrane-bound form on brain endothelium, as well as numerous other cell types in the periphery. There are 4 isoforms of AP in humans encoded by 4 separate genes (gene names are in italics): intestinal alkaline phosphatase (IAP; *ALPL*), placental alkaline phosphatase (PLAP; *ALPP*), germinal alkaline phosphatase (GCAP; *ALPPL2*), and tissue non-specific alkaline phosphatase (TNAP; *ALPL*). TNAP, also known as bone/liver/kidney AP, is the most abundant AP isoform in humans and rodents. TNAP is the only isoenzyme of AP detected in the human brain and has long been used as a marker of brain endothelium, although its presence has also been detected in neurons.

The cellular and molecular mechanisms underlying TNAP’s functional role in brain endothelium and BBB are unclear; however, results from numerous studies across several species strongly suggest that TNAP plays a role in the transport of specific classes of compounds across the BBB. Brain endothelial cell TNAP protein may also help facilitate cross-talk between the BBB and other cell types; in addition, a number of molecules, including cyclic adenosine monophosphate (cAMP) and IL-6, have been shown to modulate TNAP expression. Deracinois et al found that TNAP expression was increased in brain endothelial cells, and that the inhibition of AP activity using levamisole, a non-specific AP inhibitor, increased brain endothelial cell permeability. We speculate that TNAP’s regulatory phosphatase activity on a number of BBB endothelial proteins may play an important role in maintaining BBB integrity, thereby alleviating septic encephalopathy or long-term brain dysfunction. As shown in Figure 3 of our in vivo study, TNAP enzyme activity appears to be upregulated in CLP-injured mice compared with their sham-injured counterparts. However, the mechanistic function of TNAP in the BBB remains to be elucidated in sepsis and is currently being investigated in our lab.

Other brain-specific functions of TNAP have been described as having a role in proliferation and migration in the developing nervous system, control of axonal growth formation and maturation of synapse, and dephosphorylation of extracellular phospho-tau in AD. Despite the absence of a clearly elucidated mechanism for TNAP in brain endothelium and neurons, emerging data suggest that the manipulation of the AP activity can influence disease outcomes. For example, pretreatment of experimental autoimmune encephalomyelitis (EAE) mice with bovine intestinal AP reduced the disease severity through a mechanism that caused a reduction in neuroinflammation and autoreactive T regulatory cell proliferation. Increased levels of AP have also been detected in blood of epileptic patients, suggesting its applicability as a potential biomarker for many neurological diseases.

**Pharmaceutical Interventions in Sepsis**

**Antimicrobial delivery across the BBB**

There is a current shift in the literature regarding specific pathogens that play a role in the inflammatory response associated with sepsis. Knowing the microbe implicated in sepsis best
dictates which appropriate antibiotic or other type of treatment is required. Whereas older studies implicate Gram-negative bacteria necessitating antibiotic intervention in sepsis, newer studies have begun to reveal that other pathogens like Gram-positive bacteria, fungi, and viruses can also stimulate the inflammatory response associated with sepsis. According to recent epidemiologic studies, Gram-positive bacteria cause approximately 50 000 more cases of sepsis every year in the United States compared with Gram-negative bacteria. Because factors such as the type of inciting pathogen and the site of infection are good predictors of patient mortality, it is essential that the antimicrobial agent be used to effectively treat the disease as well as any subsequent side effects such as neurological impairment. Currently, this is often difficult and impractical in the hospital, as the time from diagnosis to initiation of treatment is critical. In addition, the sepsis field has faced many difficulties in developing effective therapeutics to treat sepsis. Currently, there are no Food and Drug Administration (FDA)-approved drugs used to treat sepsis as there have been numerous clinical trial failures over the past 15 years. This difficulty stems from our incomplete knowledge about the mechanisms that underlie the disease pathology associated with sepsis.

Initial suspicion of sepsis necessitates the use of non-specific broad-spectrum antibiotics against Gram-positive (eg, vancomycin) and Gram-negative (eg, imipenem) bacteria before blood cultures become available. Following pathogen identification, the initial antibiotic regimen is often narrowed to a single agent. Although numerous human and animal studies have shown an increase in survival following antibiotic administration, limited published data are available on whether or how antibiotics are able to penetrate the BBB. More importantly, the effects of antibiotics and other antimicrobials on brain function and sepsis-associated neurological impairment are not well studied. Thus, a complete knowledge of drug mechanisms in the CNS is essential for identifying an appropriate drug regimen and therapeutic approach to treat the neurological impairment associated with sepsis.

The most common drug classes used to treat sepsis are shown in Table 3. Drugs belonging to the fluoroquinolone and sulfonamide classes, along with rifampin, metronidazole, and chloramphenicol, readily enter the brain regardless of disease state. Antimicrobials that do not normally penetrate the brain may readily cross into the BBB, or into the cerebrospinal fluid (CSF), due to opening of TJ’s and reduced P-gp activity. In contrast, more hydrophilic and larger drugs such as vancomycin

Figure 3. Alkaline phosphatase (AP) activity in the brain and BBB. (A) Histological staining for AP activity shows decreased TNAP enzyme activity in the cortex of septic male mice (10-15 months old) subjected to the cecal ligation and puncture (CLP) model of experimental sepsis. C57BL/6J mice were subjected to CLP or a sham injury and brains were harvested 24 hours later. (B) Graph shows the quantification of cortical AP enzyme activity in CLP (n = 3; 52.49 ± 0.1094) versus sham (n = 3; 53 ± 0.1142) mice (sections = 3 per mouse; data represented as mean ± SEM, *P < .05, t(4) = 3.384, unpaired Student’s t-test, scale bar = 115 µm). AP activity was assessed in 35-µm brain sections with the BCIP/NBT AP Substrate Kit (Vector Laboratories, Burlingame, CA) following previously published methods.

BBB, blood-brain barrier; TNAP, tissue non-specific alkaline phosphatase.
and members of the β-lactam class of antibiotics do not readily enter the CSF or brain unless the meninges are inflamed.187

Intravenous immunoglobulin administration

Active advancement in understanding the pathophysiology of sepsis has led to the use of emerging immunomodulatory adjuvants to target septic encephalopathy. The acute phase of sepsis is embodied by a diminished production of immunoglobulin G (IgG) because the immune system takes 1 to 2 weeks to generate sufficient IgG levels needed to respond to an infection.188 Therefore, the observed reduction in IgG levels has warranted the use of immunomodulatory intravenous immunoglobulins (IVIgs) in sepsis patients.188,189 The mechanisms by which IVIg operates are complex and remain unclear.190,191 However, it has been proposed that the IVIg polyclonal IgG domains exert an immunomodulatory function by binding Fc receptors (FcγRs) found on many immune cell types (ie, microglia, endothelial, leukocyte). IVIg binding is thought to neutralize endotoxins/cytokines, inhibit complement activation, and block leukocyte adhesion molecule binding.90,192,193

Several studies have demonstrated the efficacy of IVIg treatment in sepsis. Esen et al193 showed that the administration of IVIg enriched with IgA and IgM improved BBB permeability, reduced sickness behavior, and improved mortality in CLP–induced rats. Further investigations by the same group revealed that the improvement in BBB integrity, neuronal destruction, and amelioration of septic encephalopathy is mediated by the inhibition of complement 5a (C5a).90 A small number of clinical meta-analytical studies have reported a decrease in mortality of sepsis patients administered IVIg; this finding complements the results observed by Esen et al.193,194–196 In contrast, a larger double-blinded randomized control trial conducted in the International Neonatal Immunotherapy Study (INIS) showed no significant differences in mortality following IVIg administration.192,197 Note that the studies included in the meta-analysis showing a decrease in mortality after IVIg administration consisted of relatively small patient populations, which suggests that these studies may not have been sufficiently powered to detect meaningful differences in mortality.191,192,198,199

Taken together, the apparent effects of IVIg in sepsis treatment appear to be promising yet inconclusive. The high cost of treatment combined with unknown mechanism(s) of action and limited efficacy in a number of publications have made it difficult for organizations like the FDA and the Surviving Sepsis Campaign Guidelines (SSCG) to recommend IVIg as an adjuvant in sepsis treatment.188,190,192

Conclusions

The heterogeneous presentation and causes of sepsis are profoundly linked to its variable clinical outcomes. Chronic neurological impairment is an increasingly common yet poorly understood clinical outcome. Understanding the mechanistic determinants of BBB integrity during sepsis is critically important for sepsis diagnosis and implementation of treatment options to ensure a positive prognosis. Importantly, long-term prognosis in sepsis survivors is linked to both transient and permanent alterations in BBB permeability and function. Thus, targeting the BBB should be incorporated as part of a short- and long-term therapeutic strategy in all sepsis patients. The development of therapies that inhibit BBB dysfunction and stimulate normal BBB function will limit mortality, suppress neuroinflammation, and improve neurological outcomes in sepsis survivors. Equally important for effective sepsis treatment is a better understanding of how antimicrobials and other drugs (eg, IVIgs or vasopressors) used in treating sepsis readily cross the BBB, and whether there are any additional unknown impacts on brain function. Taken together, the identification of cellular and molecular mechanisms that preserve BBB function

Table 3. Antimicrobials used in sepsis treatment and their corresponding CNS penetration.

| DRUG CLASS     | EXAMPLE(S)                   | LIPOPHILICITY | CNS PENETRATION | REFS |
|----------------|------------------------------|---------------|-----------------|------|
| β-lactam       | Penicillin, piperacillin     | + +           | + +             | 176,177 |
| Fluoroquinolones | Ciprofloxacin, moxifloxacin | + + +         | + + +           | 178  |
| Tetracyclines  | Doxycycline                  | − −           | 0               | 179  |
| Glycopeptides  | Vancomycin                   | − −           | +               | 181  |
| Anti-tuberculosis | Pyrazinamide, isoniazid     | −             | + + +           | 182  |
| Anti-fungal    | Amphotericin B               | − −           | + +             | 183  |
| Anti-parasitic | Pyrimethamine, albendazole  | + +           | +               | 184,185 |

CNS, central nervous system.

* indicates higher, − indicates lower, and 0 indicates neutral or no change.
in the face of sepsis will provide valuable therapeutic targets to treat numerous inflammatory disorders that target both the brain and the periphery—ranging from AD and stroke to diabetes and cardiovascular disease.

Author Contributions
DCN and CMB contributed to manuscript design, compilation of manuscript, and creation of figures and tables. ALB wrote section on tissue non-specific alkaline phosphatase (TNAP). ASM contributed to the table on antimicrobials used in sepsis. JG contributed to the section on BBB overview. BPL-W contributed to the section on neuroinflammation and BBB permeability. SAB performed tissue alkaline phosphatase (TNAP) enzyme stain and image analysis. WJG contributed to the section on neuroinflammation and BBB permeability. PRL contributed to sections on pharmacological intervention in sepsis. All authors reviewed the final documents and provided comments.

ORCID iD
Candice M Brown https://orcid.org/0000-0001-5845-0221

REFERENCES
1. Martin AB, Hartman M, Benson J, Catlin A. National Health Expenditure Accounts Team. National health spending in 2014: faster growth driven by coverage expansion and prescription drug spending. Health Aff (Millwood). 2016;35:150–160.
2. Goffon TE, Young GB. Sepsis-associated encephalopathy. Nat Rev Neurol. 2012;8:557–566.
3. Widmann CN, Heneka MT. Long-term cerebral consequences of sepsis. Lancet Neurol. 2014;13:630–636.
4. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–810.
5. Laslo I, Tracy D, Molnar E, Fazakas J. Sepsis: from pathophysiology to individualized patient care. J Immunol Res. 2015;2015:510436.
6. Vincent JL, de Mendonca A, Carrau R, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1996;24:1638–1644.
7. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:762–774.
8. Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathways and outcomes. Expert Rev Anti Infect Ther. 2012;10:701–706.
9. Mahapatra S, Heffner ME. Shock. Septic (Sepsis). Treasure Island, FL: StatPearls; 2018.
10. Macdonald SP, Williams JM, Shetty A, et al. Review article: sepsis in the emergency department—part 1: definitions and outcomes. Emerg Med Australas. 2017;29:639–652.
11. Morr M, Lukasza A, Rubig E, Ravensthal H, Kumpers P. Sepsis recognition in the emergency department—impact on quality of care and outcome. BMC Emerg Med. 2017;17:11.
12. Fleischmann C, Thomas-Rueddel DO, Hartmann M, et al. Hospital incidence and mortality rates of sepsis. Disch Arztebl Int. 2016;113:159–166.
13. Ikkander KN, Osuchowski MF, Stearns-Kurosawa DJ, et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev. 2013;93:1247–1288.
14. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–1554.
15. Esper AM, Moss M, Lewis CA, Niubet R, Mannino DM, Martin GS. The role of infection and comorbidity: factors that influence disparities in sepsis. Crit Care Med. 2006;34:2576–2582.
16. Kingsley SM, Bhat BV. Differential paradigms in animal models of sepsis. Curr Infect Dis Rep. 2016;18:26.
17. Parker SJ, Watkins PE. Experimental models of gram-negative sepsis. Br J Surg. 2001;88:22–30.
18. Danzler R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun. 2001;15:7–24.
19. Zandt N, Uebe A, Neumann B, et al. Essential role of gamma interferon in survival of colon ascendent stent peritonitis, a novel marine model of abdominal sepsis. Infect Immun. 1998;66:2300–2309.
20. Braegger T, Koerner P, Kessler W, et al. Colon ascendent stent peritonitis (CASP)—a standardized model for polymicrobial abdominal sepsis. J Virol. 2010;46:2299.
21. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticogulant activated protein C. J Exp Med. 2007;204:2439–2448.
22. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1484–1490.
23. Wyler F, Neurze JM, Rudolph AM. Effects of endotoxin on distribution of cardiac output in unanesthetized rabbits. Am J Physiol. 1970;219:246–251.
24. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res. 1990;49:186–196.
25. Fink MP, Fiallo V, Stein KL, Gardiner WM. Systemic and regional hemodynamic changes after intraperitoneal endotoxin in rabbits: development of a new model of the clinical syndrome of hyperdynamic sepsis. Circ Shock. 1987;22:73–81.
26. Burma JA, Holmman B, Storvick M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov. 2005;4:854–865.
27. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014;40:463–475.
28. Barichello T, Sayana P, Grittharvan VV, et al. Long-term cognitive outcomes after sepsis: a translational systematic review. Mol Neurobiol. 2019;56:186–251.
29. Polas G, Ugan RA, Cadics E, Halicz Z. Sepsis and septic shock: current treatment strategies and new approaches. Eurasian J Med. 2017;49:53–58.
30. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045.
31. Kirsten TB, Galvao MC, Reis-Silva TM, Quitóres-Hazardasson N, Bernardi MM. Zinc prevents sickness behavior induced by lipopolysaccharides after a stress challenge in rats. PLoS ONE. 2015;10:0120263.
32. Kessler W, Diedrich S, Menges P, et al. The role of the vagus nerve: modulation of the inflammatory reaction in murine polymicrobial sepsis. Mediators Inflamm. 2012;2012:467620.
33. Mitsui T, Fukutani K, Yamagawa M, et al. Truncal vagotomy temporarily decreases the pro- and anti-inflammatory cytokine levels in the small intestine. Surg Today. 2014;44:1123–1127.
34. Tracey KJ. The inflammatory reflex. Nature. 2002;420:853–859.
35. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458–462.
36. Li N, Li, Z, Xiang H, Wang X, Zhang X, Li J. Protective effects of vagus nerve stimulation on rats with sepsis-associated encephalopathy. Zhongguo Wei Zhong Bing Ji Yi Xue. 2012;25:509–513.
37. Eriksson MA, Banks WA. Neuroimmune axes of the blood-brain barriers and blood-brain interfaces: bases for physiological regulation, disease states, and pharmacological interventions. Pharm Res. 2018;70:278–314.
38. Quan N. In-depth coverage: spectrum and kinetics of neuroimmune afferent pathways. Brain Behav Immun. 2014;40:1–8.
39. Mazeraul A, Pascal O, Verdonk F, Hening M, Chreiten F, Sharhar T. Neuroanatomy and physiology of brain dysfunction in sepsis. Clin Chim Acta. 2016;373:333–345.
40. Reyes EP, Abarza S, Cortes PP, Fernandez R. LPS-induced e-Fox activation in TNF-α neurons and pharmacological treatment in septic rats are suppressed by bilateral carotid chemodenervation. Exp Adv Med Biol. 2012;578:185–190.
41. Annane D, Sharhar T. Cognitive decline after sepsis. Lancet Respir Med. 2015;3:64–69.
42. Pun BT, Dunn J. The sedation of critically ill adults: part 1: assessment. The first in a two-part series focuses on assessing sedated patients in the ICU. Am J Nurs. 2007;107:40–48; quiz 49.
43. Pytel P, Alexander JJ. Pathogenesis of septic encephalopathy. Curr Opin Neurol. 2009;22:283–287.
44. Hosokawa K, Gaspard N, Su F, Oddo M, Vincent JL, Taccone FS. Clinical neuro-physiological assessment of sepsis-associated brain dysfunction: a systematic review. Crit Care. 2014;18:674.
45. Chaudhry N, Duggal AK. Sepsis associated encephalopathy. Adv Med. 2014;7:672302.
46. Gilmore EJ, Gaspard N, Choi HA, et al. Acute brain failure in severe sepsis: a prospective study in the medical intensive care unit utilizing continuous EEG monitoring. Intensive Care Med. 2015;41:686–694.
47. Semmler A, Widmann CN, Okulla T, et al. Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors. J Neurol Neurosurg Psychiatry. 2013;84:62–69.
48. Piazza O, Russo E, Cotena S, Esposito G, Tufano R. Elevated S100B levels do not correlate with the severity of encepalopathy during sepsis. Br J Anaesth. 2007;99:518–521.
49. Sinclair JF, Balakrishnan G, Skeoch CH, Hallworth D. Cerebral blood flow is reduced in patients with sepsis syndrome. Crit Care Med. 1990;18:684.
50. Brassard P, Kim YS, van Lieshout J, Secher NH, Rosenmeier JB. Endotoxemia reduces cerebral perfusion but enhances dynamic cerebrovascular autoregulation at reduced arterial carbon dioxide tension. Crit Care Med. 2012;40:1873–1878.
51. Semmler A, Hermann S, Marmann F, et al. Septis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation. 2008;5:38.
52. Taccone FS, Su F, Pierrakos C, et al. Cerebral microcirculation is impaired during sepsis: an experimental study. Crit Care. 2010;14:R140.
53. Crippa IA, Subira C, Vincent JL, et al. Impaired cerebral autoregulation is associated with brain dysfunction in patients with sepsis. Crit Care. 2008;12:227.
54. Goodson CM, Rosenblatt K, Rivera-Lara L, Nyquist P, Hogue CW. Cerebral blood flow autoregulation in sepsis for the intensivist: why its monitoring may be the future of individualized care. J Intensive Care Med. 2018;33:63–73.
55. Polito A, Eischwald F, Maho AL, et al. Endotoxin mimetic in the acute setting of human septic shock. Crit Care Med. 2017;13:R204.
56. Crippa IA, Subira C, Vincent JL, et al. Impaired cerebral autoregulation is associated with brain dysfunction in patients with sepsis. Crit Care. 2008;12:227.
57. Gunther ML, Morandi A, Krauskopf E, et al. The association between brain volumes, delirium duration, and cognitive outcomes in intensive care unit survivors: the VISIONS cohort magnetic resonance imaging study. Crit Care Med. 2016;40:2022–2032.
58. Shankar HC, Chandra D, de la Grandmaison GJ, Brouland JP, Hopkinson NS, Francoise G. The neuropathology of septic shock. Brain Pathol. 2004;14:23–31.
59. Janz DR, Abel TW, Jackson JC, Gunther ML, Heckscher S, Ely EW. Brain autopsy findings in intensive care unit patients previously suffering from delirium: a pilot study. J Crit Care. 2010;25:538.e7–538.e12.
60. Crippa IA, Subira C, Vincent JL, et al. Impaired cerebral autoregulation is associated with brain dysfunction in patients with sepsis. Crit Care. 2008;12:227.
61. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus 150/0.55 versus 200/1.3% albumin for fluid resuscitation in severe sepsis. JAMA. 2012;367:1901–1911.
62. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:1235–1243.
63. Perren A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012;367:124–134.
64. Avila AA, Kimberg EC, Sherwin NK, Taylor RD. The use of fluids in sepsis. Curr. Opin. Crit. Care. 2016;8:e528.
65. Semler MW, Rice TW. Sepsis resuscitation: fluid choice and dose. Crit Care. 2012;367:124–134.
66. Ma D, Hossain M, Rajakumaraswamy N, et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol. 2004;502:87–97.
67. Maes M, Lin A, Kenis G, Egyed B, Bosmans E. The effects of noradrenaline and alpha-2 adrenoceptor agents on the production of monocyctic products. Psychiatry Res. 2000;96:245–252.
68. Taniguchi T, Kidani Y, Kanakura H, Tsuchimoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med. 2004;32:1322–1326.
69. Pandharipande PP, Girard TD, Jackson JC, et al. Long-term cognitive impairment after critical illness. JAMA. 2010;304:1787–1794.
70. Varatharaj A, Gavriela L. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2016;57:60–1.
71. Vaucher SC, Effert H, Bruck W, Nau R. Septic encephalopathy and septic encephalitis. Expert Rev Anti Infect Ther. 2017;15:121–132.
72. Eun F, Ohun G, Ozcan PE, et al. Neuroprotective effects of intravenous immunoglobulin are mediated through inhibition of complement activation and apoptosis in a rat model of sepsis. J Neuroinflammation. 2017;5:1.
73. Semmler A, Okulla T, Sastre M, Dumitrescu-Ozimek L, Heneka MT. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J Chem Neuroanat. 2005;30:144–157.
74. Curioso FL, Her J, Fernandes A, et al. Systemic inflammation in early neonatal mice induces transient and lasting neurodegenerative effects. J Neuroinflammation. 2015;12:82.
75. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119:7–35.
76. Cataldo CHR, Santos-Junior NN, da Costa LHA, Souza AO, Alberici LC, Rocha MJA. Brain oxidative stress during experimental sepsis is attenuated by simvastatin administration. Mol Neurobiol. 2017;54:7008–7018.
77. Skibsted S, Jones AE, Puarkich MA, et al. Biomarkers of endothelial cell activation in early sepsis. Shock. 2013;39:427–432.
78. Gilks N, Katheroe T, Matsuoka N, Hayakawa M, Hoshino H, Kato H. Serial changes in neutrophil-endothelial activation markers during the course of sepsis associated with disseminated intravascular coagulation. Thorax. 2005;61:902–100.
79. Reis PA, Extrato V, da Silva TI, et al. Statins decrease neuroinflammation and prevent cognitive impairment after critical illness. PLoS Pathog. 2012;8:e1003099.
80. Zrazry T, Hofbinger R, Berger T, et al. Pro-inflammatory activation of microglia in the brain of patients with sepsis [published online ahead of print May 27, 2018]. Neupathol Appl Neurobiol. doi:10.1111/nan.12502.
81. Singh BH, Newrwall MW, Zeng X, et al. Celiac laparotomy and puncture results in long-term central nervous system myeloid inflammation. PLoS ONE. 2016;11:e0149136.
82. Shankar T, Gray F, Lorin de la Grandmaison G, et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase knockdown after death from septic shock. Lancet. 2003;362:1799–1805.
83. van der Poll T, de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17:407–420.
84. Zeng H, He X, Tuo QH, Liu DF, Zhang QG, Chen JX. LPS causes pericyte loss and microvascular dysfunction via disruption of Sirt3/angiopoietins/Tie-2 and HIF-1alpha/Notch3 pathways. Sci Rep. 2016;6:20931.
85. Fang J, Lian Y, Xie K, Cai S, Wei P. Epigenetic modulation of neuronal apoptosis and cognitive functions in sepsis-associated encephalopathy. Neurol Sci. 2014;35:283–288.
86. Heming N, Mazeraud A, Verdonk F, Bozza FA, Cretien F, Shanhar T. Neuroanatomy of sepsis-associated encephalopathy. Crit Care. 2017;21:65.
87. Wei H, Cao X, Zeng Q, et al. Ghenrel inhibits proinflammatory responses and prevents cognitive impairment in septic rats. Crit Care Med. 2015;43:e143–e150.
106. Messaris E, Memos N, Chatiagiani E, et al. Time-dependent mitochondrial-mediated programmed neuronal cell death prolongs survival in sepsis. Crit Care Med. 2004;32:1764–1770.

107. De Luca C, Colangeli AM, Alberghina L, Papa M. Neuro-immune hemostasis: homeostasis and diseases in the central nervous system. Front Cell Neurosci. 2018;12:459.

108. Abbott NJ, Parabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. NeuroToxicol. 2010;31:17–35.

109. Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Neurosurg Metab. 2013;35:437–449.

110. Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR. Molecular determinants of blood-brain barrier permeation. Ther Deliv. 2015;6:961–971.

111. Adkins CE, Mittapalli RK, Manda VK, et al. P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. Front Pharmacol. 2013;4:436.

112. Zhao Z, Nelson AR, Berchtold C, Zlokovic BV. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163:1044–1079.

113. Keaney J, Campbell M. The dynamic blood-brain barrier. FEBS J. 2015;282:4067–4079.

114. Ransohoff RM, Schafer D, Vincent A, Blachere NE, Bar-Osr A. Neuroinflammation: ways in which the immune system affects the brain. Neurotherapeutics. 2015;12:896–909.

115. Annane D, Bellissant E, Cavallio J-M. Septic shock. Lancet. 2005;365:63–78.

116. Akrout N, Sharshar T, Annane D. Mechanisms of brain signaling during sepsis. Curr Neuropharmacol. 2009;7:296–301.

117. Pan W, Kastin AJ. TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice. Exp Neurol. 2002;174:193–200.

118. Nishijima T, Piriz J, Duflot S, et al. Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuroreport. 2010;21:673–679.

119. Hughes CG, Patel MB, Pandharipande PP. Pathophysiology of acute brain dysfunction. Crit Care Med. 2007;35:2186–2190.

120. Adkins CE, Mittapalli RK, Manda VK, et al. P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. Front Pharmacol. 2013;4:436.

121. Heneka MT, Loschmann PA, Gleichmann M, et al. Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal excitotoxicity triggered by nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal excitotoxicity. J Neurochem. 1998;71:88–94.

122. Leist M, Volbracht C, Kuhnle S, Fava E, Ferrando-May E, Nicotera P. Caspase-dependent mitochondrial dysfunction prolongs survival in sepsis. J Cereb Blood Flow Metab. 2004;24:1281–1289.

123. Leist M, Volbracht C, Kuhnle S, Fava E, Ferrando-May E, Nicotera P. Caspase-dependent programmed neuronal cell death prolongs survival in sepsis. J Cereb Blood Flow Metab. 2004;24:1281–1289.

124. Wang X, Ren X, Wang Y, et al. Traumatic brain injury research and expression limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. FEBS J. 2009;7:296–301.

125. Wu H, Deng R, Chen X, et al. Caveolin-1 is critical for lymphocyte trafficking and tumor necrosis factor-alpha/lipopolysaccharide-induced cytochrome c release from CNS mitochondria. J Neurochem. 2000;74:1281–1289.

126. Lopes Pinheiro MA, Kroon J, Hoogenboezem M, et al. Acid sphingomyelinase-mediated apoptosis in neuronal excitotoxicity triggered by nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal excitotoxicity. J Neurochem. 2006;97:750–764.

127. Sowa G. Role of caveolin proteins in sepsis. Pediatr Ther. 2012;2012:991.

128. Wang X, Ren X, Wang Y, et al. Traumatic brain injury research and expression limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. FEBS J. 2009;7:296–301.

129. Hopkins RO. Sepsis, oxidative stress, and brain injury. Crit Care Med. 2007;35:2233–2234.

130. Barichello T, Fortunato JJ, Vitali AM, et al. Oxidative variables in the rat brain after sepsis induced by cecal ligation and perforation. Crit Care Med. 2006;34:886–899.

131. Papadopoulos MC, Davies DC, Ross MF, Tighe D, Bennett ED. Pathophysiology of septic encephalopathy: a review. Crit Care Med. 2000;28:3019–3024.

132. Clementi E, Brown GC, Feilisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protection against glutathione. Prog Neurol Sci. 1998;5:763–766.

133. Brooks P, Bolanos JP, Heales SJ. The assumption that nitric oxide inhibits mitochondrial ATP synthesis is correct. FEBS Lett. 1999;446:261–263.

134. Cunha A, Rali R. Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys. 1996;328:309–316.

135. Clementi E, Brown GC, Feilisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protection against glutathione. Prog Neurol Sci. 1998;5:763–766.

136. d’Avila JC, Santiago AP, Amancio RT, Galina A, Oliveira MF, Bozza FA. Septic encephalopathy: a review. Neurotoxicology. 2004;25:91–101.

137. Hopkins RO. Sepsis, oxidative stress, and brain injury. Crit Care Med. 2007;35:2233–2234.

138. Barichello T, Fortunato JJ, Vitali AM, et al. Oxidative variables in the rat brain after sepsis induced by cecal ligation and perforation. Crit Care Med. 2006;34:886–899.

139. Papadopoulos MC, Davies DC, Ross MF, Tighe D, Bennett ED. Pathophysiology of septic encephalopathy: a review. Crit Care Med. 2000;28:3019–3024.

140. Clementi E, Brown GC, Feilisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protection against glutathione. Prog Neurol Sci. 1998;5:763–766.
163. Wang X, Li S. Effect of small-dose levosimendan on mortality rates and organ functions in Chinese elderly patients with sepsis. *Clin Interv Aging*. 2017;12:917–921.

164. Kawazoe Y, Miyamoto K, Morimoto T, et al. Effect of dexmedetomidine on mortality and ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized controlled trial. *Clin Interv Aging*. 2015;10:1927–1933.

165. Leaf DE, Raed A, Donnino MW, Ginde AA, Waikar SS. Randomized controlled trial of calciotrol in sepsis. *Am J Respir Crit Care Med*. 2014;190:533–541.

166. Vincent JL, Marshall JC, Dellinger RP, et al. Tactoferin in severe sepsis: results from the phase II/III oral tachoferrin in sepsis trial. *Crit Care Med*. 2015;43:1832–1838.

167. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med*. 2017;43:304–377.

168. Kim BY, Ng AM, Persaud AK, et al. Antibiotic timing and outcomes in sepsis. *Clin J Am Soc Nephrol*. 2018;13:524–529.

169. Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. *Crit Care Med*. 2014;42:1749–1755.

170. Liu VX, Fielding-Singh V, Greene JD, et al. The timing of early antibiotics and mortality in critically ill patients. *Am J Med*. 2018;135:524–529.

171. Coopersmith CM, Amiot DM, 2nd Stromberg PE, et al. Antibiotics improve survival and alter the inflammatory profile in a murine model of sepsis from *Pseudomonas aeruginosa* pneumonia. *Shock*. 2003;19:408–414.

172. Choudhury S, Kannan K, Pule Addison M, et al. Combined treatment with atorvastatin and imipenem improves survival and vascular functions in mouse model of sepsis. *Vasc Pharmacol*. 2015;71:139–150.

173. Vyas D, Javid B, Depstrey D, Buchman TG, Hothchickis RS, Coopersmith CM. Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. *Am J Physiol Regul Integr Comp Physiol*. 2005;289:R1048–R1053.

174. Marshall JC. Why have clinical trials in sepsis failed? "Trends Mol Med". 2005;11:111–118.

175. Shin SH, Kim KS. Treatment of bacterial meningitis: an update. *Expert Opin Pharmacother*. 2012;13:2189–2206.

176. Hamano N, Nishi K, Onose A, et al. Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock. *J Intensive Care*. 2013;1:4.

177. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. *Am Rev Respir Dis*. 1985;131:347–348.

178. Soares MO, Welson NJ, Harrison DA, et al. Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial. *Crit Care*. 2014;18:649.

179. Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)—beyond immunodeficiencies and neurology. *Clin Exp Immunol*. 2009;158:23–33.

180. Di Rosa R, Pietrosanti M, Luzi G, Salemi S, D’Amelio R. Polyclonal intravenous immunoglobulin. *Expert Opin Biol Ther*. 2009;111:511–516.

181. Albanese J, Leone M, Bruguierolle Ayen ML, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. *Antimicrob Agents Chemother*. 2000;44:1356–1358.

182. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the use of different routes of administration. *Trends Mol Med*. 1993;148:650–655.

183. Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. *Expert Opin Drug Metab Toxicol*. 2007;3:573–581.

184. McLeod R, Mack D, Foss R, et al. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. *Trends Mol Med*. 2003;9:32–46.

185. von Wedel-Padlon M, Wolfe P, Gulla HJ. Regulation of major efflux transporters from a guideline-based performance improvement program. *Crit Care Med*. 2014;42:1749–1755.

186. Volbeda M, Wetterslev J, Gluud C, Zijlstra JG, van der Horst IC, Keus F. Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med*. 2015;41:1220–1234.

187. Shin SH, Kim KS. Treatment of bacterial meningitis: an update. *Expert Opin Pharmacother*. 2012;13:2189–2206.

188. Hamano N, Nishi K, Onose A, et al. Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock. *J Intensive Care*. 2013;1:4.

189. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. *Am Rev Respir Dis*. 1985;131:347–348.

190. Soares MO, Welson NJ, Harrison DA, et al. Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial. *Crit Care*. 2014;18:649.

191. Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)—beyond immunodeficiencies and neurology. *Clin Exp Immunol*. 2009;158:23–33.

192. Di Rosa R, Pietrosanti M, Luzi G, Salemi S, D’Amelio R. Polyclonal intravenous immunoglobulin: an important additional strategy in sepsis? *Eur J Intern Med*. 2014;25:511–516.

193. Esen F, Sentrük E, Özcan PE, et al. Intravenous immunoglobulins prevent the breakdown of the blood-brain barrier in experimentally induced sepsis. *Crit Care Med*. 2012;40:1214–1220.

194. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. *Clin Infect Dis*. 2004;39:38–46.

195. Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. *Cochrane Database Syst Rev*. 2013;9:CD001090.

196. Kreymann KG, de Heer G, Nierhaus A, Schellinger PD, Klingebiel T, Rixen D. Intravenous immunoglobulins as adjunctive therapy for sepsis or septic shock. *Crit Care Med*. 2003;31:2667–2685.

197. Darenberg J, Thendayn S, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. *Clin Infect Dis*. 2003;37:333–340.

198. Laupland KB, Kirlpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. *Crit Care Med*. 2007;35:2686–2692.

199. Henrich M, Fehrle K, Ostermann H, et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. *Crit Care Med*. 2006;34:1129–1135.